Evaluation of Hearing Threshold in Patients with Beta Thalasemia Major Receiving Regular ChelationTherapy with Desferrioxamine (DFO)

The aim of this study was the evaluation of hearing threshold in patients with beta thalasemia major. For this purpose, ۱۷۸ patients who were under regular chelation therapy with desferrioxamine (DFO) were selected and underwent ear, nose, throat examinations and audiological evaluations. Patients were between ۴ to ۲۵ years old and ۵۴.۹% were male and ۴۵.۱% were female. Three patients were excluded from the study due to middle ear disease and tympanic membrane perforation. Mean hearing threshold was ۱۲.۴۶db. The incidence of hearing loss in speech frequencies was ۱.۸% and there was a correlation between hearing threshold increase and the duration of disease and desferrioxamine consumption. But no correlation was found between hearing threshold and serum ferritin level (mean ۴۰۴۶ ng/ml) or DFO dose (mean=۳۸.۶۸mg/kg/day).

کلیدواژه ها:

Hearing threshold ، Beta thalasemic major ، Desferrioxamine